Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · IEX Real-Time Price · USD

2.155

-0.105 (-4.65%)

Jul 22, 2024, 9:32 AM EDT - Market open

Taysha Gene Therapies Employees

Taysha Gene Therapies had 52 employees as of December 31, 2023. The number of employees decreased by 13 or -20.00% compared to the previous year.

Employees

52

Change (1Y)

-13

Growth (1Y)

-20.00%

Revenue / Employee

$272,231

Profits / Employee

-$2,269,327

Market Cap

430.95M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	52	-13	-20.00%
Dec 31, 2022	65	-113	-63.48%
Dec 31, 2021	178	140	368.42%
Dec 31, 2020	38	-	-

Related Stocks

Company Name	Employees
Health Catalyst	1,300
Nano-X Imaging	164
Absci	155
Nkarta	150
C4 Therapeutics	145
Korro Bio	102
Kyverna Therapeutics	96
Aura Biosciences	89

Employee Rankings

TSHA News

17 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
26 days ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
26 days ago - Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
26 days ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
4 weeks ago - What's Going On With Taysha Gene Therapies Stock Tuesday? - Benzinga
4 weeks ago - Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome - GlobeNewsWire
5 weeks ago - Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting - GlobeNewsWire
2 months ago - Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire